

LES
pop-upclasses
1.
The Proposed
TRIPS COVID-19 Patent Waiver
October 7 at 8am EDT | 2pm CEST
► lesi.org

1

LESI Pop-Up Classes: Popping up near you...via zoom!

LES pop-upclasses
LES pop-upclasses
LES pop-upclasses
LES pop-upclasses
LES pop-upclasses
LES pop-upclasses
LES pop-upclasses
LES pop-upclasses
LES pop-upclasses

2

Part 1: Panel Discussion (45 minutes)

- Welcome (Dana Colaruli, Peter Ling)
- Introduction of the Topic (Julie Barnes-Weise)
- Introductory Remarks by each speaker (5 minutes max)
- General discussion led by Julie (All)



Page 3

3

Part 2: Break-out sessions (45 minutes)

- **Session 1: Will the Waiver Help?**
Is the waiver worth it also when considering its downsides? Are there better/faster/cheaper solutions that achieve the same goal? Is the waiver based on misconceptions about patents?
- **Session 2: The TRIPS-Agreement is waived – The Day After**
What would the consequences of a TRIPS-Waiver for various stakeholders be? What further steps would be needed to deploy vaccines and COVID-drugs globally once the TRIPS-Agreement is waived?
- **Session 3: The TRIPS-Agreement is not waived – The Day After**
If the TRIPS Council does not reach consensus, what else could be done to ensure a fair and swift distribution of vaccines and COVID-related drugs? Can licensing (including compulsory licensing) help? What are the main licensing challenges with respect to COVID-vaccines?



Page 4

4





POP-UPCLASSES

Speakers

- **(Moderator) Julia Barnes-Weise**, Executive Director, Global Healthcare Innovation Alliance Accelerator
- **Wolf Meier-Ewert**, Counsellor (IP Division), World Trade Organization (WTO)
- **Jim Pooley**, Former Deputy Director General, World Intellectual Property Organization (WIPO)
- **Andrew Casey**, President & CEO, BIOTECANADA
- **Cesare Galli**, Attorney at law, Full Professor, University of Parma
- **Archana Shanker**, Senior Partner, Anand and Anand

Page 5

5

Part 2: Break-out sessions (45 minutes)

- **Session 1: Will the Waiver Help?**
Is the waiver worth it also when considering its downsides? Are there better/faster/cheaper solutions that achieve the same goal? Is the waiver based on misconceptions about patents?
- **Session 2: The TRIPS-Agreement is waived – The Day After**
What would the consequences of a TRIPS-Waiver for various stakeholders be? What further steps would be needed to deploy vaccines and COVID-drugs globally once the TRIPS-Agreement is waived?
- **Session 3: The TRIPS-Agreement is not waived – The Day After**
If the TRIPS Council does not reach consensus, what else could be done to ensure a fair and swift distribution of vaccines and COVID-related drugs? Can licensing (including compulsory licensing) help? What are the main licensing challenges with respect to COVID-vaccines?



POP-UPCLASSES


Page 6

6

Who is LESI?

The **Licensing Executives Society International (LESI)** is an umbrella association of 33 national and regional Member Societies in more than 90 countries serving more than 6500 individuals.

- A global network of businesses and professionals for 50 years
- 33 member societies in more than 90 countries
- Creating, protecting, and commercializing innovation, and managing and monetizing IP
- Business leaders, IP managers, licensing executives, financiers, licensing companies, brokers
- Experts in law, valuation, protection, transfer, and enforcement of IP
- Advancing the business of intellectual property



LESI: Advancing the Business of Intellectual Property Globally

7



8

8